COMPELLING RISK/REWARD: Credit Suisse analyst Benjamin Chaiken upgraded Six Flags ($SIX) to Outperform from Neutral with a price target of $53, up from $52. The shares offer a "compelling risk/reward" following the recent selloff, Chaiken tells investors in a research note. The analyst had concerns around Six Flags' ability to price, but with the stock down 20%, he believes this is "baked into the stock." The recent pullback has less to do with fundamentals decelerating and more to do with overly optimistic expectations, says Chaiken. STARBUCKS DOWNGRADED: Baird analyst David Tarantino downgraded Starbucks ($SBUX) to Neutral from Outperform with a price target of $116, down from $126. While he is still optimistic about the company's long-term fundamental outlook, he is less constructive near-term due to an increasingly uncertain backdrop in China, Tarantino tells investors. He sees some other risk factors that could linger for the balance of FY22 as well, making him less bullish on the shares at the stock's current valuation, Tarantino added.HUNTINGTON'S DATA UPDATE: Raymond James analyst Danielle Brill downgraded uniQure ($QURE) to Outperform from Strong Buy with a price target of $58, down from $75, after the company reported initial one-year safety findings from the first four patients enrolled in the low-dose cohort of the Phase 1/2 trial with their gene therapy AMT-130 for Huntington's Disease. The stock is currently reflecting zero value for Huntington's and she thinks the selloff is "overdone," but Brill said that since there was a lack of clear evidence of target engagement she no longer expects "meaningful de-risking" of this program until 12-months data are reported for the high-dose cohort in the first half of 2023. Though still optimistic about AMT-130's therapeutic potential, her downgrade reflects "the protracted timeline to value inflection," Brill said.T. ROWE PRICE UPGRADE: BMO Capital analyst James Fotheringham upgraded T. Rowe Price ($TROW) to Outperform from Market Perform with a price target of $246, down from $253. The analyst now sees high single-digit percentage upside to consensus EPS expectations following the announced takeover of Oak Hill Advisors. Fotheringham said the acquisition marks T. Rowe's first significant M&A deal in over two decades and adds scale and capabilities in a high-growth vertical of Alternatives.HONEYWELL INITIATED WITH A BUY: Mizuho analyst Brett Linzey initiated coverage of Honeywell ($HON) with a Buy rating and $245 price target. The company's "late cycle drivers" in aerospace, non-residential and industrial end markets are picking up, Linzey tells investors in a research note. However, he believes "patience is warranted" for Honeywell shares as supply issues continue to impact the business.PRODUCTION NUMBERS 'MEANINGLESS': Piper Sandler analyst Alexander Potter is a "bit surprised" to see Rivian Automotive ($RIVN) trading lower by 8% post last night's earnings. There wasn't enough new information in the Q3 results to warrant a revised thesis, "so we're not sure why someone would sell the stock based on these results," Potter tells investors in a research note. Rivian's production in 2021 will be a few hundred units lower than anticipated, but at this early stage in the company's production ramp, numbers like this are "meaningless," says the analyst. He reiterates an Overweight rating on the shares with a $48 price target.Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .